TAP2 and neoplasm: As shown in Figure 8E, most MHC I molecules, including HLA-A, HLA-C, HLA-E, HLA-F, TAP1, TAP2, and TAPBP (all P < 0.05), were upregulated in PTPRD/PTPRT mutant patients, indicating enhanced anti-tumor immunity in PTPRD/PTPRT mutant patients.